Paragon 28, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023
January 08, 2024 at 09:00 am EST
Share
Paragon 28, Inc. provided revenue guidance for the fourth quarter and full year 2023. For the quarter, company expects net revenue to be in a range of $60.3 million to $60.6 million.
For the year, company expects net revenue to be in a range of $216.1 million to $216.4 million.
Paragon 28, Inc. is a medical device company focused on the foot and ankle orthopedic market. The Company provides orthopedic solutions, procedural approaches and instrumentation that cover a range of foot and ankle ailments, including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. To treat these painful, debilitating or even life-threatening conditions, it provides a portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. Its broad suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. It has developed a comprehensive portfolio of foot and ankle surgical systems. Each system typically includes plates, screws, staples, nails, advanced joint and bone replacements, orthobiologics, and other implantation instruments and disposables specifically designed for the particular surgical system.